version April 14, 2008
HOVON 68 CLL – CASE REPORT FORMS
Pełna wersja do pobrania w pliku PDF:
Ho68 CRF 14042008
A randomized phase III study in previously untreated patients with biological high-risk CLL:
Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab